Key facts
- This page summarizes Glenn A. Eisenberg's Form 4 filing for LABORATORY CORP OF AMERICA HOLDINGS (LH).
- 5 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 03 Nov 2022, 17:04.
Glenn A. Eisenberg - 01 Nov 2022 Form 4 Insider Report for LABORATORY CORP OF AMERICA HOLDINGS (LH)
- Reporting relationship
- Chief Financial Officer, EVP
- Issuer ticker
- LH
- Reported as of
- 01 Nov 2022
- Net transaction value
- -$1,190,251
- SEC form
- 4
- Accepted by SEC
- 03 Nov 2022, 17:04:30 UTC
- Prior SEC filing
- 28 Sep 2022
- Next SEC filing
- 06 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sandra D. van der Vaart, Attorney-in-Fact for Glenn A. Eisenberg
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Glenn A. Eisenberg filed Form 4 for LABORATORY CORP OF AMERICA HOLDINGS (LH) on 03 Nov 2022.
Change
- Previous filing in this sequence was filed on 28 Sep 2022.
- Current net transaction value: -$1,190,251.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LH
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +12,032
- Change %
- +44%
- Price
- Shares after
- 39,190
- Date
- 01 Nov 2022
- Ownership
- Direct
- Footnotes
- F1
LH
transaction
Common Stock
Tax liability
- Transaction value
- $1,190,251
- Shares
- -5,348
- Change %
- -14%
- Price
- $222.56
- Shares after
- 33,842
- Date
- 01 Nov 2022
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LH
transaction
Derivative
Performance Share Unit
Award
- Transaction value
- $0
- Shares
- +9,170
- Change %
- Price
- $0.000000
- Shares after
- 9,170
- Date
- 01 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,170
- Exercise price
- Footnotes
- F3, F4, F5
LH
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +9,170
- Change %
- +55%
- Price
- $0.000000
- Shares after
- 25,876
- Date
- 01 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,170
- Exercise price
- Footnotes
- F1, F6
LH
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -12,032
- Change %
- -46%
- Price
- $0.000000
- Shares after
- 13,844
- Date
- 01 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,032
- Exercise price
- Footnotes
- F1, F7, F8
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 8 footnotes
Footnote F1
Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
Footnote F2
Stock withholding to satisfy tax withholding obligations.
Footnote F3
Performance Share Unit granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan.
Footnote F4
Each Performance Share Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
Footnote F5
The Performance Share Units vest in full upon the filing of the Company's Quarterly Report on Form 10-Q for the first quarter of 2024, subject to both continued service and a performance condition related to the Issuer's contemplated spin-off transaction.
Footnote F6
The Restricted Stock Units vest in full on April 15, 2024.
Footnote F7
The Restricted Stock Units that have vested were part of a grant that vested in three installments as follows: 30% of the Restricted Stock Units vested on November 1, 2020; 30% of the Restricted Stock Units vested on November 1, 2021; and 40% of the Restricted Stock Units vested on November 1, 2022, with the third installment subject to a relative total shareholder return ("TSR") modifier that could have adjusted the third installment of the Restricted Stock Units upward or downward 25% based on our three-year cumulative relative TSR but ultimately did not result in an adjustment.
Footnote F8
This number reflects the aggregate number of Restricted Stock Units held by the reporting person.